USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/20020
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPetrenko, N.-
dc.date.accessioned2022-02-07T08:50:17Z-
dc.date.available2022-02-07T08:50:17Z-
dc.date.issued2012-
dc.identifier.citationPETRENKO, N. Peculiarities of premenstrual syndrome treatment in women with hyperthyroidism. In: MedEspera: the 4th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2012, p. 61.en_US
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/20020-
dc.description.abstractToday among all endocrinological disease in women thyroid pathology is the second only to diabetes. Premenstrual syndrome (PMS) plays a leading role in reducing the quality of life for women of the reproductive age. The manifestations of PMS are particularly worse in women with hyperthyroidism. We examined 35 patients with premenstrual syndrome and / or irregular menstruation with concomitant hyperthyroidism. In the examined patients the nature of the menstrual cycle, the degree of manifestation of premenstrual syndrome, the level of PRL and its biologically active fraction (BFA), LH, FSH, estradiol (E2), progesterone (Pg) were analyzed. In order to correct the detected impairments a dose of up to 30 drops of Mastodinon twice a day for three menstrual cycles was used.Mastodinon caused a significant decrease in the levels of total prolactin (15,5 ± 1,0) IU /1, BFA to (8,5 ± 0,7) IU /1 and its contents - to the (54,7 ± 4, 5)%, significant increase in LH concentration to (9,3 ± 0,6) IU /1, FSH - to (7,7 ± 0,7) IU /1, E2 - up (179,2 ± 9,9) ng / L and Pg - to (20,5 ± 1,8) mg /1. Restoration of ovulatory cycles occurred in 86.0% of patients, regular menstrual cycles were established in 94.3% of patients, all patients had normal length of the menstrual cycle, duration and volume of menstrual bleeding. Use of Mastodinon led to the elimination of Algodysmenorrhea, emotional and psychological, neurovegetative, vegetative vascular and endocrine-metabolic manifestations of PMS in 94.3% of patients. After using Mastodinon for 3 menstrual cycles breast secretions continued only in 4 (11.4%) patients. Thus the use of Mastodinon had positive effects on the menstrual function and PMS by eliminating hyperprolactinemia and restoring the pituitary regulation of reproductive function.en_US
dc.language.isoenen_US
dc.publisherState Medical and Pharmaceutical University Nicolae Testemitanu, Medical Students and Residents Association, Scientific Association of Students and Young Doctorsen_US
dc.relation.ispartofMedEspera: The 4th International Medical Congress for Students and Young Doctors, May 17-19, 2012, Chisinau, Republic of Moldovaen_US
dc.titlePeculiarities of premenstrual syndrome treatment in women with hyperthyroidismen_US
dc.typeOtheren_US
Appears in Collections:MedEspera 2012

Files in This Item:
File Description SizeFormat 
PECULIARITIES_OF_PREMENSTRUAL_SYNDROME_TREATMENT_IN_WOMEN_WITH_HYPERTHYROIDISM.pdf760.83 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback